WO2001027613A3 - Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl - Google Patents

Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl Download PDF

Info

Publication number
WO2001027613A3
WO2001027613A3 PCT/EP2000/010058 EP0010058W WO0127613A3 WO 2001027613 A3 WO2001027613 A3 WO 2001027613A3 EP 0010058 W EP0010058 W EP 0010058W WO 0127613 A3 WO0127613 A3 WO 0127613A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
acid
antigen
complex
mammal
Prior art date
Application number
PCT/EP2000/010058
Other languages
English (en)
French (fr)
Other versions
WO2001027613A2 (de
Inventor
Christian Reiter
Gerhard Cullmann
Petra Heppner
Achim Ringeis
Heidemarie Mueller
Eva Haindl
Original Assignee
Connex Ges Zur Optimierung Von
Christian Reiter
Gerhard Cullmann
Petra Heppner
Achim Ringeis
Heidemarie Mueller
Eva Haindl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27439941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001027613(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BR0014734-6A priority Critical patent/BR0014734A/pt
Priority to AU77871/00A priority patent/AU7787100A/en
Priority to JP2001530573A priority patent/JP2003511698A/ja
Priority to ES00967861.6T priority patent/ES2194782T5/es
Priority to SI200030127T priority patent/SI1232392T1/xx
Application filed by Connex Ges Zur Optimierung Von, Christian Reiter, Gerhard Cullmann, Petra Heppner, Achim Ringeis, Heidemarie Mueller, Eva Haindl filed Critical Connex Ges Zur Optimierung Von
Priority to DE50001665T priority patent/DE50001665D1/de
Priority to IL14906200A priority patent/IL149062A0/xx
Priority to EP00967861.6A priority patent/EP1232392B2/de
Priority to DK00967861T priority patent/DK1232392T3/da
Priority to AT00967861T priority patent/ATE236398T1/de
Priority to CA002387473A priority patent/CA2387473C/en
Publication of WO2001027613A2 publication Critical patent/WO2001027613A2/de
Publication of WO2001027613A3 publication Critical patent/WO2001027613A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

Die Erfindung betrifft ein Verfahren zum Nachweis einer Infektion eines Säugers mit einem Säure-resistenten Mikroorganismus, wobei man (a) eine Stuhlprobe des Säugers unter Verwendung (aa) eines Rezeptors unter Bedingungen inkubiert, die eine Komplexbildung eines Antigens aus dem Säure-resistenten Mikroorganismus mit dem Rezeptor erlauben; oder (ab) zwei unterschiedliche Rezeptoren unter Bedingungen inkubiert, die eine Komplexbildung eines Antigens aus dem Säure-resistenten Mikroorganismus mit den beiden Rezeptoren erlauben und wobei der Rezeptor gemäß (aa) oder die Rezeptoren gemäß (ab) ein Antigen spezifisch bindet/binden, das zumindest bei einem Teil der Säuger nach der Darmpassage eine Struktur aufweist, die der nativen Struktur oder der Struktur entspricht, gegen die ein Säuger nach Infektion oder Immunisierung mit dem Säure-resistenten Mikroorganismus oder einem Extrakt oder Lysat davon oder einem Protein daraus oder einem Fragment davon oder einem synthetischen Peptid Antikörper produziert; und (b) die Bildung mindestens eines Antigen-Rezeptorkomplexes gemäß (a) nachweist. Vorzugsweise ist der Säure-resistente Mikroorganismus ein Bakterium, insbesondere Helicobacter pylori, Helicobacter hepaticus, Campylobacter jejuni oder Mycobacterium tuberculosis. Ferner bevorzugt ist, daß der Rezeptor/die Rezeptoren an ein Epitop/Epitope einer Katalase bindet. Ferner betrifft die Erfindung diagnostische und pharmazeutische Zusammensetzungen und Testvorrichtungen, welche die vorgenannten Komponenten enthalten sowie diese enthaltende Verpackungen.
PCT/EP2000/010058 1999-10-12 2000-10-12 Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl WO2001027613A2 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002387473A CA2387473C (en) 1999-10-12 2000-10-12 Improved method for the detection of acid resistant microorganisms in a stool
IL14906200A IL149062A0 (en) 1999-10-12 2000-10-12 Improved method for detecting acid resistant microorganisms in the stool
JP2001530573A JP2003511698A (ja) 1999-10-12 2000-10-12 便中の酸耐性微生物の改良された検出方法
ES00967861.6T ES2194782T5 (es) 1999-10-12 2000-10-12 Procedimiento mejorado de detección de bacterias acidorresistentes del género Helicobacter en las heces
SI200030127T SI1232392T1 (en) 1999-10-12 2000-10-12 Improved method for the detection of acid resistant bacteria of the genus helicobacter in stool
BR0014734-6A BR0014734A (pt) 1999-10-12 2000-10-12 Método melhorado para detectar microorganismos resistentes a ácido na evacuação
DE50001665T DE50001665D1 (de) 1999-10-12 2000-10-12 Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
AU77871/00A AU7787100A (en) 1999-10-12 2000-10-12 Improved method for the detection of acid resistant microorganisms in a stool
EP00967861.6A EP1232392B2 (de) 1999-10-12 2000-10-12 Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
DK00967861T DK1232392T3 (da) 1999-10-12 2000-10-12 Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring
AT00967861T ATE236398T1 (de) 1999-10-12 2000-10-12 Verbessertes verfahren zum nachweis von säure- resistenten bakterien der gattung helicobacter im stuhl

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP99120351.4 1999-10-12
EP99120351 1999-10-12
EP00105592 2000-03-16
EP00105592.0 2000-03-16
EP00107028.3 2000-03-31
EP00107028 2000-03-31
EP00110110.4 2000-05-10
EP00110110 2000-05-10

Publications (2)

Publication Number Publication Date
WO2001027613A2 WO2001027613A2 (de) 2001-04-19
WO2001027613A3 true WO2001027613A3 (de) 2001-10-18

Family

ID=27439941

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2000/010058 WO2001027613A2 (de) 1999-10-12 2000-10-12 Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl
PCT/EP2000/010057 WO2001027612A2 (de) 1999-10-12 2000-10-12 Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010057 WO2001027612A2 (de) 1999-10-12 2000-10-12 Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl

Country Status (16)

Country Link
US (1) US7129053B1 (de)
EP (2) EP1232392B2 (de)
JP (2) JP2003511697A (de)
CN (1) CN1382259A (de)
AT (1) ATE236398T1 (de)
AU (2) AU1137301A (de)
BR (1) BR0014734A (de)
CA (1) CA2387473C (de)
DE (1) DE50001665D1 (de)
DK (1) DK1232392T3 (de)
ES (1) ES2194782T5 (de)
IL (1) IL149062A0 (de)
PT (1) PT1232392E (de)
SI (1) SI1232392T1 (de)
TR (1) TR200201006T2 (de)
WO (2) WO2001027613A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7960600A (en) * 1999-10-29 2001-05-14 Wakamoto Pharmaceutical Co., Ltd. Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
JP3504633B2 (ja) 1999-10-29 2004-03-08 わかもと製薬株式会社 ヘリコバクター・ピロリへの感染を判定する検査方法及び検査試薬
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6706474B1 (en) 2000-06-27 2004-03-16 Board Of Trustees Of The University Of Illinois Nucleic acid enzyme biosensors for ions
WO2002014541A1 (en) * 2000-08-11 2002-02-21 Wakamoto Pharmaceutical Co., Ltd. Method of examining infection with helicobacter pylori and diagnostic kit
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
JP4763149B2 (ja) * 2001-05-10 2011-08-31 わかもと製薬株式会社 ヘリコバクター・ピロリへの感染を判定する検査方法
FI118061B (fi) 2001-09-24 2007-06-15 Beanor Oy Menetelmä ja bioanturi analyysiä varten
FI115166B (fi) * 2001-12-31 2005-03-15 Biofons Oy Diagnostisia menetelmiä
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
HUE030806T2 (hu) 2002-05-02 2017-05-29 Wyeth Holdings Llc Calicheamicin származék-hordozó konjugátumok
US6890719B2 (en) 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
US7534560B2 (en) 2002-05-10 2009-05-19 The Board Of Trustees Of The University Of Illinois Simple catalytic DNA biosensors for ions based on color changes
US7612185B2 (en) 2003-03-07 2009-11-03 The Board Of Trustees Of The University Of Illinois Nucleic acid biosensors
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
CA2548381C (en) * 2003-12-05 2015-12-01 Fuso Pharmaceutical Industries, Ltd. Cytolethal distending toxins and detection of campylobacter bacteria using the same as a target
US7999071B2 (en) 2003-12-12 2011-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
US7485419B2 (en) 2004-01-13 2009-02-03 The Board Of Trustees Of The University Of Illinois Biosensors based on directed assembly of particles
JP4672263B2 (ja) * 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
EP1686378B1 (de) * 2005-01-28 2010-11-17 DNT Scientific Research, LLC Durchflussdiffusor für immunologische Testvorrichtungen und Verfahren
PT2645106T (pt) 2005-04-04 2017-09-18 Biogen Ma Inc Método para avaliar uma resposta imune a um agente terapêutico
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
BRPI0614366A2 (pt) 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
US7892734B2 (en) 2005-08-11 2011-02-22 The Board Of Trustees Of The University Of Illinois Aptamer based colorimetric sensor systems
WO2007024633A2 (en) * 2005-08-23 2007-03-01 Response Biomedical Corporation Multi-directional immunochromatographic assays
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
EP3620469A1 (de) 2006-02-28 2020-03-11 Biogen MA Inc. Verfahren zur behandlung von entzündungs- und autoimmunerkrankungen mit natalizumab
CN101437541A (zh) 2006-03-03 2009-05-20 伊兰药品公司 用那他珠单抗治疗炎性疾病和自身免疫病的方法
US7799554B2 (en) 2006-03-16 2010-09-21 The Board Of Trustees Of The University Of Illinois Lateral flow devices
WO2008089248A2 (en) 2007-01-19 2008-07-24 The Board Of Trustees Of The University Of Illinois Amphiphilic substances and triggered liberation from lipid vesicles
US8058415B2 (en) 2007-04-24 2011-11-15 The Board Of Trustees Of The University Of Illinois Aptamer- and nucleic acid enzyme-based systems for simultaneous detection of multiple analytes
EP2156370B1 (de) 2007-05-14 2011-10-12 Historx, Inc. Abteilungsauftrennung durch pixelcharakterisierung unter verwendung von bilddatenclusterung
ES2599902T3 (es) 2007-06-15 2017-02-06 Novartis Ag Sistema y método de microscopio para obtener datos de muestra normalizados
US8409800B2 (en) 2007-07-16 2013-04-02 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for copper detection
US8568690B2 (en) 2007-07-31 2013-10-29 The Board Of Trustees Of The University Of Illinois MRI contrast agents and high-throughput screening by MRI
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
US8367416B2 (en) 2007-08-10 2013-02-05 The Board Of Trustees Of The University Of Illinois Nucleic acid based fluorescent sensor for mercury detection
US7978258B2 (en) 2007-08-31 2011-07-12 Historx, Inc. Automatic exposure time selection for imaging tissue
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US9240043B2 (en) 2008-09-16 2016-01-19 Novartis Ag Reproducible quantification of biomarker expression
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US8062893B2 (en) 2008-10-10 2011-11-22 The Board Of Trustees Of The University Of Illinois Fluorescent sensor for mercury
AU2010203709B2 (en) 2009-01-06 2014-05-22 Galenagen, Llc Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
HRP20221390T1 (hr) 2010-01-11 2023-01-06 Biogen Ma Inc. Analiza za antitijela jc virusa
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
US8815156B2 (en) 2010-07-19 2014-08-26 Andalyze, Inc. Sensor housing and reagent chemistry
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
CN102539424B (zh) * 2011-12-23 2013-11-20 李雄 一种pH值乙醇法舌苔快速尿素酶的检测方法及试剂盒
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
CN102980884A (zh) * 2012-11-29 2013-03-20 江苏创生生物技术有限公司 胃黏膜样品中幽门螺旋杆菌的化学发光免疫测定法
US10119976B2 (en) 2013-05-28 2018-11-06 Biogen Ma Inc. Method of assessing risk of PML
MX2017007249A (es) 2014-12-05 2018-01-25 Memorial Sloan Kettering Cancer Center Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos.
WO2017070594A1 (en) 2015-10-21 2017-04-27 William John Hall Bed bugs detection device
US10768172B2 (en) 2015-10-21 2020-09-08 Redcoat Solutions, Inc. Anti-bed bug monoclonal antibodies and methods of making and uses thereof
EP3383913A4 (de) * 2015-12-04 2019-10-30 Memorial Sloan-Kettering Cancer Center Antikörper gegen fc-rezeptor-like 5 und verfahren zur verwendung
WO2019187271A1 (ja) 2018-03-30 2019-10-03 株式会社バイオメディカル研究所 検査キットおよび検査方法
CN111499751B (zh) * 2020-05-06 2021-03-19 云南省农业科学院园艺作物研究所 一种用于检测白菜过氧化氢酶的单克隆抗体及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN113388616B (zh) * 2021-07-27 2022-04-26 中国海洋大学 特异性结合幽门螺旋杆菌的核酸适配体、生物元件、生物传感器及检测方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
US5607863A (en) * 1991-05-29 1997-03-04 Smithkline Diagnostics, Inc. Barrier-controlled assay device
WO1997034149A1 (en) * 1996-03-12 1997-09-18 Stefan Svenson Method of diagnosing a mycobacterial disease and immunoassay kit
WO1998024885A1 (en) * 1996-12-06 1998-06-11 Sanitaria Scaligera S.P.A. Helicobacter pylori antigen having an apparent molecular weight of 16±2 kda, a specific antibody, and its use for the detection of said antigen
US5932430A (en) * 1996-05-09 1999-08-03 Meridian Diagnostics, Inc. Immunoassay for H. pylori in fecal specimens
WO1999044066A1 (en) * 1998-02-25 1999-09-02 Helitech Biomedical Inc. Encapsulated diagnostics for alimentary analytes
WO1999049889A1 (en) * 1998-03-31 1999-10-07 The United States Of America, As Represented By The Secretary Of Agriculture Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens
WO2000026671A1 (de) * 1998-10-29 2000-05-11 Connex Gmbh Nachweis von säure-resistenten mikroorganismen im stuhl

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856421T2 (de) * 1987-04-27 2000-12-14 Unilever Nv Spezifische Bindungstestverfahren
AU676672B2 (en) * 1992-02-21 1997-03-20 Novartis Ag Brofaromine as an agent for treating post-traumatic stress
JP3448071B2 (ja) * 1992-03-24 2003-09-16 ロート製薬株式会社 糞便中ヘモグロビン検出用装置
FI92882C (fi) 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
US5716791A (en) 1996-05-09 1998-02-10 Meridian Diagnostics, Inc. Immunoassay for H. pylori in fecal specimens
US6433728B1 (en) 1999-01-22 2002-08-13 Lear Automotive Dearborn, Inc. Integrally molded remote entry transmitter

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
US5607863A (en) * 1991-05-29 1997-03-04 Smithkline Diagnostics, Inc. Barrier-controlled assay device
WO1997034149A1 (en) * 1996-03-12 1997-09-18 Stefan Svenson Method of diagnosing a mycobacterial disease and immunoassay kit
US5932430A (en) * 1996-05-09 1999-08-03 Meridian Diagnostics, Inc. Immunoassay for H. pylori in fecal specimens
WO1998024885A1 (en) * 1996-12-06 1998-06-11 Sanitaria Scaligera S.P.A. Helicobacter pylori antigen having an apparent molecular weight of 16±2 kda, a specific antibody, and its use for the detection of said antigen
WO1999044066A1 (en) * 1998-02-25 1999-09-02 Helitech Biomedical Inc. Encapsulated diagnostics for alimentary analytes
WO1999049889A1 (en) * 1998-03-31 1999-10-07 The United States Of America, As Represented By The Secretary Of Agriculture Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens
WO2000026671A1 (de) * 1998-10-29 2000-05-11 Connex Gmbh Nachweis von säure-resistenten mikroorganismen im stuhl

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KRISHNAMURTHY P. ET AL.: "Helicobacter pylori containing only cytoplasmic urease is susceptible to acid.", INFECTION AND IMMUNITY, vol. 66, no. 11, November 1998 (1998-11-01), pages 5060 - 5066, XP002160658 *
MAKRISTATHIS A ET AL.: "Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens from pediatric patients before and after eradication tharapy.", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 38, no. 10, October 2000 (2000-10-01), pages 3710 - 3714, XP000983473 *

Also Published As

Publication number Publication date
EP1232392B2 (de) 2014-04-02
PT1232392E (pt) 2003-08-29
WO2001027613A2 (de) 2001-04-19
ATE236398T1 (de) 2003-04-15
DK1232392T3 (da) 2003-07-28
TR200201006T2 (tr) 2002-11-21
AU1137301A (en) 2001-04-23
WO2001027612A3 (de) 2001-10-11
EP1232392A1 (de) 2002-08-21
DE50001665D1 (de) 2003-05-08
AU7787100A (en) 2001-04-23
SI1232392T1 (en) 2003-10-31
JP2003511697A (ja) 2003-03-25
EP1232392B1 (de) 2003-04-02
EP1336850A1 (de) 2003-08-20
ES2194782T5 (es) 2014-08-20
CA2387473A1 (en) 2001-04-19
ES2194782T3 (es) 2003-12-01
IL149062A0 (en) 2002-11-10
CA2387473C (en) 2010-02-02
US7129053B1 (en) 2006-10-31
CN1382259A (zh) 2002-11-27
BR0014734A (pt) 2002-06-18
JP2003511698A (ja) 2003-03-25
WO2001027612A2 (de) 2001-04-19

Similar Documents

Publication Publication Date Title
WO2001027613A3 (de) Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl
JP6009938B2 (ja) プロカルシトニンの検出のためのイムノアッセイ
Hirota et al. Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production
JP2002529705A5 (de)
US20040023316A1 (en) New method for detecting acid-resistant microorganisms in the stool
US5294537A (en) Monoclonal antibody assay for Listeria monocytogenes
Hansbauer et al. Detection, differentiation, and identification of botulinum neurotoxin serotypes C, CD, D, and DC by highly specific immunoassays and mass spectrometry
CA2239208A1 (en) Treatment and diagnosis of infections due to helicobacter pylori
US20220363725A1 (en) Peptides and their use in diagnosis
WO2001032908A1 (fr) Anticorps monoclonal, hybridome, immunoessai et necessaire a diagnostic
US6146836A (en) Immunoassays using anti-allotypic monoclonal antibodies
Gessler et al. Immunomagnetic beads assay for the detection of botulinum neurotoxin types C and D
Ivanov et al. Effective method for synthetic peptide immobilization that increases the sensitivity and specificity of ELISA procedures
FI119990B (fi) N-peptidin kerrosimmuunimääritysmenetelmä
JP4122419B2 (ja) 便、唾液試料および生検材料中のヘリコバクターピロリおよびハイルマニの検出方法
Cao et al. Detection of spiral and coccoid forms of Helicobacter pylori using a murine monoclonal antibody
US5773235A (en) Equine arteritis virus peptides; antibodies and their use in a diagnostic test
JP5618570B2 (ja) Ｃ型肝炎ウイルスの免疫測定方法及びそれに用いる試薬キット
KR101806522B1 (ko) 병원성 대장균에 특이적인 신규한 단클론 항체, 이를 생산하는 하이브리도마, 이를 포함하는 검출용 조성물, 검출 방법 및 검출 키트
JP2015510876A (ja) 干渉ペプチド及び微生物の検出方法
WERGELAND et al. Antibodies to Staphylococcus aureus peptidoglycan and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections
WO2005037870A1 (ja) 抗体およびその用途
Ehrenberg Establishment of an ELISA and a lateral flow device for detection of European and American foulbrood including genotype-differentiation of the American foulbrood causing agent (ERIC I & ERIC II) in honey bees
Rautelin et al. Single and multiple acid extract antigens in Campylobacter serology
Oh et al. Development of sandwich enzyme-linked immunosorbent assay for a large-scale detection of porcine transmissible gastroenteritis virus in feces

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000967861

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00347/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 149062

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 530573

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008142378

Country of ref document: CN

Ref document number: 2387473

Country of ref document: CA

Ref document number: 2002/01006

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 2000967861

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000967861

Country of ref document: EP